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pericardial effusion poses a multidimensional surgical
challenge because of the advanced nature of the neoplastic
disease and its associated poor prognosis (median life
expectancy of approximately 15 weeks).1 Important vari-
ables include the type of malignancy and its potential for
treatment with systemic or radiation therapy, as well as
the general condition and hemodynamic stability of the
patient. Successful therapeutic modalities have included
pericardiocentesis with short- and long-term catheter
drainage, percutaneous drainage with intrapericardial
sclerosis, percutaneous balloon pericardiotomy, and surgi-
cal drainage with pericardial window.2 Most patients
referred for surgery seem to be those with ongoing or pre-
cardiac tamponade, necessitating urgent or emergency
drainage. There are no prospective, randomized trials
comparing these therapeutic modalities with respect to
success rate or long-term outcome.What is clear regarding
the evaluation and treatment of patients with malignant
pleural effusions is that their care should take place in a
multidisciplinary setting, with input from medical and ra-
diation oncologists, radiologists, cardiologists, oncologic
support staff, and surgeons.
In this issue of the Journal, C¸elik and colleagues3 from
Italy present their retrospective review of data from the
International Neoplastic Pericarditis Treatment Study that
compared the results of chemotherapy alone, chemotherapy
plus percutaneous drainage, and chemotherapy plus surgi-
cal drainage with pericardial window (through a left ante-
rior thoracotomy) in patients with proven malignant
pericardial effusions. Their data set included 175 patients
treated in 8 centers throughout 3 countries. The study is
unique in that it claims to be the first of its kind to compare
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to suggest both a response and survival advantage with the
latter. The message is weakened by the study’s retrospective
nature, as well as the absence of an enrollment protocol in
that patients were treated according to ‘‘institutional
preference.’’
When determining response rate and survival advantage
after drainage for malignant pericardial effusion, it is
important to place the indications for intervention into
perspective. If we assume that drainage of a malignant peri-
cardial effusion has virtually no oncologic impact, then the
most effective therapy is the one that gives the best physio-
logic response (complete drainage), yields the lowest recur-
rence rate, and is best tolerated by the patient. C¸elik and
colleagues3 have shown that both pericardiocentesis with
catheter drainage and surgical drainage with pericardial
window are well tolerated by a group of patients who tend
to be debilitated by virtue of their advanced malignancies.
Although response rate and survival were better with the
surgical approach in this study, C¸elik and colleagues3 did
not really attempt an explanation, nor have they made a
strong recommendation for the surgical approach. Although
somewhat disappointing, this is probably appropriate.
One would expect that the surgical approach would yield
more complete pericardial drainage; however, that did not
turn out to be true in this study. Although total response
(complete response group plus partial response group)
was superior in the surgical group, complete response was
almost identical between the 2 groups (29.3% for chemo-
therapy with percutaneous drainage and 31.1% for chemo-
therapy with a pericardial window). The survival advantage
associated with the surgical approach also goes unex-
plained. Was it due to a lower recurrence rate related to
the surgical approach and pericardial window, or could it
be that the surgical group had a higher number of patients
with malignancies other than lung cancer who went on to
have a response to systemic therapy? The unfortunate real-
ity is that the future of successful treatment of malignant
pericardial effusions lies not in the hands of cardiologists
or thoracic surgeons, but in those of the medical and radia-
tion oncologists who have yet to successfully treat these
advanced malignancies.
Are the results of C¸elik and colleagues3 compelling
enough to make a case for surgical drainage plus pericardial
window instead of percutaneous drainage, all in the setting
of chemotherapy? Probably not. Only a prospective, ran-
domized trial with clear-cut advantages would do that.
Furthermore, percutaneous therapy can be effective andgery c November 2014
Cohen Editorial Commentarymore practical, especially in the presence of cardiac tampo-
nade. That said, there are some situations in which the
surgical approach is clearly preferable. If the diagnosis is
in doubt (as many as 30% of patients with pericardial
effusion and a known malignancy actually have benign
pericardial effusions as a result of chemotherapy, radiation
therapy, autoimmune disease, or infection), or percutaneous
drainage is technically difficult, then the surgical approach
has clear advantages. Beyond this, it will be the oncologic
advances in the treatment of these advanced malignanciesThe Journal of Thoracic and Carthat will offer the real hope for improved results in the
future.
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